American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
August 12, 2021
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Andrea, and I appreciate all of you being with us today. Before I hand things over to management, I want to offer a few comments regarding forward-looking statements. Please be aware that any remarks made during this conference call about future expectations, plans and prospects for the company are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, due to a number of important factors, such as those covered in the company's SEC filings; among these are the annual report on Form 10-K for the year ended December 31, 2020, the quarterly report on Form 10-Q for the quarter ended March 31, 2021, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 25, 2021. No obligation is assumed by the company to update the information contained in this conference call. At this point I'd like to hand the call to Ray Stachowiak, CEO of AMS. Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everyone, and good afternoon. We appreciate you being with us for the earnings conference call covering our second quarter of 2021. I'll start things off with a few comments, and after that Craig Tagawa, who serves as our President, COO and CFO, will walk through the business and operational results. Next, Alexis Wallace, our Chief Accounting Officer, will give a financial review. After that, Craig, Alexis, Ernie Bates — our Senior Vice President, Sales and Business Development and International operations — and I will take your questions. Against last year's quarter, which felt the pandemic's deepest impact, AMS turned in a good second quarter. Year-over-year, total revenue rose 12%. We saw net income rise to $157,000 in Q2. That followed the net impact from extinguishing debt, which was $29,000 in Q1 of this year. The gain came from increased revenue, plus reductions in depreciation, selling and administrative costs, and interest expense. Shortly, Craig and Alexis will walk through the specifics. Actions we've taken over the past several quarters have improved how our operations perform. These include the balance sheet restructuring completed at year-end, as well as the debt refinancing that wrapped up in April 2021. Before we go further, I want to flag something: back on April 13, we told you we'd formed a banking tie-up with Fifth Third Bank, NA. That entity serves as the main subsidiary of Fifth Third Bancorp, a bank holding company with a diverse portfolio, based in Cincinnati, Ohio, and holding more than $200 billion in assets. Putting our signatures on that $22 million credit agreement with them represents a landmark moment for our business. Three facilities make up the arrangement — among them 2 term loans, which handled refinancing for most of what we owed on equipment and gave our working capital a boost. On top of that, we signed for a $7 million revolving line of credit, and that money will give us more room to maneuver when we're hammering out terms for projects down the road. When you add our $8.4 million cash on hand to the positive cash flow we anticipate producing during the back half of the year, AMS ends up with a war chest exceeding $15 million for upcoming projects. The refinancing delivered a number of additional advantages too, including an immediate reduction in our cost of capital and a shift into a positive working capital position. We cut our principal payments substantially — by roughly $5.9 million across the coming 12 months — and we will capture savings on interest expense while unlocking about $300,000 that had previously been restricted cash; taken together, these moves have reshaped the company's financial profile. It placed AMS squarely on the road toward achieving sustained profitability. With our broader lineup of radiation therapy devices, we're now sitting on considerable financial firepower to pursue upcoming business possibilities. At this point, I'll hand things over to Craig so he can walk us through the operational review for the second quarter. Craig?
Craig Tagawa
executiveThanks, Ray, and good afternoon to all of you. During the second quarter, total revenue rose to $4.476 million, an increase of more than 12% versus last year, which stood as the quarter hit hardest by the pandemic across the entire year. Revenue in the second quarter from the company's proton therapy system installed at Orlando Health grew 10.6% relative to the second quarter of 2020. A higher average reimbursement per fraction made up for a reduced fraction count, which is still suffering from the pandemic's ongoing effects. Total proton therapy fractions fell 17.9% to 1,109, down from 1,351. Gamma Knife revenue came in strong, rising 13% to $2.9 million. This gain reflects greater volumes along with higher average reimbursement per treatment at the company's retail sites. Our Gamma Knife Centers located in Peru and Ecuador each added to the quarter's results as well. Gamma Knife procedures rose by 7.4% to 376 in the second quarter. For centers in operation, Gamma Knife volumes climbed 18.4% over Gamma Knife volumes at those same centers during the equivalent period a year earlier. Alongside the revenue gain, the gross margin percentage rebounded to 35.9% of revenue in the second quarter, versus 22.7% of revenue in last year's second quarter. Measured in dollars, gross margin grew 77% to $1.6 million. Fueling that gross margin expansion was a $393,000 drop in depreciation and amortization, or 24%, bringing it to $1.244 million. This reduction stemmed mainly from the expiration of 1 contract in the fourth quarter of 2020 and another contract in the first quarter of 2021, plus the absence of depreciation for the impaired equipment written off at year-end. In dollar terms, the decline in depreciation and amortization more than made up for modest increases in maintenance and supplies and other direct operating costs. Selling and administrative costs likewise went down, falling 10% period-over-period, largely because of reduced legal and other fees tied to the GKCE acquisition that we closed last June. Improved revenue and reduced costs carried through to the income statement. Operating income hit $352,000, compared with an operating loss of $570,000 in the second quarter of 2020 — a favorable swing of $922,000. Net income came to $157,000, or $0.03 per share, excluding the extinguishment of debt tied to prepayment penalties charged by our former lenders stemming from the refinancing Ray discussed. The changes we've implemented boosted our cash balances, and we finished the second quarter with $8.4 million at June 30. Across the first and second quarters of 2021, we completed 2 Cobalt-60 reloads. Several other projects remain pending in our pipeline. The upgrade at Gamma Knife Center Ecuador should be finished in late 2021 or early 2022. It will rank among the few Gamma Knife units anywhere in South America. We also intend to perform a Cobalt-60 reload in the fourth quarter, based on a contract extension executed recently; we keep holding many discussions with potential clients regarding our expanded product line. Having said that, I'll hand things over now to Alexis, who will walk us through the financials in detail. Alexis?
Alexis Wallace
executiveThanks, Craig, and hello everyone this afternoon. Before I get into my prepared comments, I'd like to point you toward the Q2 earnings press release that we issued earlier today. If you need a copy, it's available on our site, ashs.com, by going to the Investors tab and then Press Releases. Let's now turn to our results for the second quarter. During the 3 months that ended June 30, 2021, revenue climbed 12.2%, reaching $4.476 million, which compares with $3.991 million during the same period in 2020. As for the proton therapy system the company has installed at Orlando Health in Florida, revenue for the second quarter increased 10.6%, hitting $1.549 million, versus $1.401 million in the second quarter of 2020. In the second quarter, we delivered 1,109 proton therapy fractions in total. That's down 17.9% compared with the 1,351 proton therapy fractions we had in the second quarter of 2020. For our Gamma Knife business, revenue increased 13%, reaching $2.927 million in the second quarter of 2021, up from $2.590 million in the second quarter of 2020. Gamma Knife procedures totaled 376 in the second quarter of 2021, a 7.4% gain from 350 in the same period a year earlier. Our gross margin in the second quarter of 2021 was $1.607 million, up 77.2%, and represented 35.9% of revenue. In the second quarter of 2020, gross margin was $907,000, or 22.7% of revenue. For the three-month period, selling and administrative expenses dropped 9.9%, landing at $1.090 million. In the same stretch a year before, that figure stood at $1.210 million. When it came to operating income, the second quarter of 2021 delivered $352,000. That contrasts with an operating loss of $570,000 during the second quarter of 2020 — a favorable shift of $922,000. As for the bottom line, net loss during the second quarter totaled $87,000, equivalent to $0.01 per diluted share. A year earlier, in the second quarter of 2020, the net loss was $483,000, or $0.08 per diluted share. Within the current period's net loss sits a pretax charge of $401,000 tied to debt extinguishment. When you leave out a net charge of $244,000, accounting for minority interest and income taxes, net income came to $157,000, which works out to $0.03 for each diluted share. For the second quarters of 2021 and 2020, the fully diluted weighted average common shares outstanding stood at $5.802 million and $6.077 million, respectively. Adjusted EBITDA, which is a non-GAAP financial measure, reached $1.829 million in the second quarter of 2021, up from $1.437 million in the same period of 2020. Cash, cash equivalents and restricted cash added up to $8.437 million as of June 30, 2021, versus $4.325 million at December 31, 2020. At June 30, 2021, shareholders' equity was $23.714 million, equal to $4.04 for every outstanding share. At the end of 2020, on December 31, shareholder equity stood at $23.650 million, equal to $4.08 for each share then outstanding. With that, the prepared section of what we have to say is finished. Andrea, we'd now like to give the call back to you so questions can begin.
Leonard Dunn
analystRight. The business has been turned around now, but you're still stuck with that pricey office space, which — I'd been hoping you would have been able to get out of by this point. Has anything moved forward on that front?
Ray Stachowiak
executiveLenny, it's Ray here. Those efforts are still ongoing on our end. So far, though, they haven't worked out. You're likely aware that office space demand is down, and in our attempts to cut what we spend on that line item, good fortune simply hasn't shined on us.
Leonard Dunn
analystAnd what's the end date on that lease?
Ray Stachowiak
executiveMy understanding is there are a couple of years still left on it. Craig, do you happen to have those details with you?
Craig Tagawa
executiveYeah, my guess is that we're still a few years out. It is on our list, though. That said, like Ray said, we haven't managed to get there, so we're still in a holding pattern.
Leonard Dunn
analystAll right. Regarding the fresh equipment you're looking to put out — or lease, rather — have any prospects come your way? You've been at this for roughly 6 months now. My assumption was that a deal would exist by this point.
Ray Stachowiak
executiveLenny, I believe I can state with certainty that additional prospects have indeed arrived, and the response to that is an unequivocal yes. That said, going into greater detail would likely be a mistake on my part. These prospects are generating momentum for us. And along those lines, we're doing everything we can to advance our strategic direction.
Leonard Dunn
analystAll right, and regarding the proton beams — you've taken the 2 contracts with Mevion off the books, though the capability to use them remains. A few of you are aware, are you still chasing the chance of securing placements in that area?
Ray Stachowiak
executiveThat's absolutely still in our product bag, and we'd go after any such opportunities. Those chances have been scarce, particularly over these past 15, 16 months while the coronavirus has been around; the count of hospital systems considering technology at that level has, I can say with pretty solid confidence, dropped considerably as a result. That said, you're correct — we hold that right to those deposits with Mevion, and we intend to make use of it.
Leonard Dunn
analystAll right. Since that is obviously — even if installing it comes at a somewhat steeper cost, it is plainly the finest set of treatments out there for patients. And my sense is that the authoritative standing of the surgeons would lead them to persuade a hospital to proceed with an installation.
Ray Stachowiak
executiveLenny, I share that view.
Leonard Dunn
analystYour book value right now sits just a touch above $4, if you want to be cautious about it. On a typical day, and that's how we trade most of the time, the share price is well under that. So investors really aren't facing any exposure there at all. So with in-person road shows possibly coming back, is there anything you're doing to get into that...
Ray Stachowiak
executiveYeah, I'd say that possibility exists. Our view of where this company is headed has become considerably more favorable, certainly as far as I'm concerned. And looking at how much stock changes hands on an average day, that number has risen quite a bit. Along the way, some retail investors have shown interest in us. If someone asked me to boil down what happened in our second quarter, I'd probably do it with two straightforward ideas. The first idea: strip out the loss tied to extinguishing debt, and we posted net income of $157,000 for the second quarter, versus $29,000 in the first quarter. That may not amount to a lot of money overall, but the direction is encouraging. The second idea — the way I'd describe how we performed in the second quarter and where the company stands — is $15 million. We closed out the second quarter holding $8.4 million in cash. A $7 million line of credit is there for us to draw on. Nothing at all is borrowed against that $7 million line of credit; we have upwards of $15 million ready to put to work, and putting it to work is exactly our aim.
Leonard Dunn
analystAll right. When it comes to what you're able to sell, do you see yourselves bringing anything new into the portfolio?
Ray Stachowiak
executiveMy sense is that our range of products has grown quite a bit, though we still approach things through the lens of radiation therapy equipment — machines that give off radiation to treat cancer. That strikes me as a solid niche for us.
Leonard Dunn
analystThat's my view as well, since with a larger number of units out there to absorb the fixed costs, a great deal of that incremental revenue would drop straight through to the bottom line.
Ray Stachowiak
executiveWithout a doubt.
Leonard Dunn
analystAll right, that covers everything I wanted to ask. Our outlook is long-term. Still, should you keep posting better results each quarter, I suppose the stock price will ultimately sort itself out — though I'd argue a bit more visibility would help.
Ray Stachowiak
executiveThanks, Lenny. Final remarks.
Ray Stachowiak
executiveAndrea, thank you. And thanks to all of you for being with us today. Our confidence in what lies ahead for American Shared Hospital Services has not wavered. Should anything be unclear, you are welcome to reach out to us directly. We will hold our third quarter conference call in mid-November. I hope you make the most of what remains of your summer, and do take care. Have a pleasant remainder of the evening. Goodbye.
Operator
operatorThat brings us to the end of this call. We appreciate your joining us for today's presentation, and you're free to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.